Skip to main content
BCLI logo

BCLI · Brainstorm Cell Therapeutics Inc.

$0.90 -0.03 (-3.23%) At close · Jul 28
Market Cap
$9.93M
Shares
11.03M

Daily short-sale volume published by FINRA from its trade-reporting facilities. It measures how many shares were sold short each day as a share of total volume — a daily flow, not the total outstanding short position.

Short Volume

Date Short Volume Short Exempt Total Volume Short %
2026-07-28 4,480 0 12,714 35.2%
2026-07-27 1,202 0 6,931 17.3%
2026-07-23 800 0 4,979 16.1%
2026-07-22 3,800 0 8,454 44.9%
2026-07-21 5,058 0 7,759 65.2%
2026-07-17 7,600 0 15,018 50.6%
2026-07-16 4,965 0 14,072 35.3%
2026-07-15 1,353 0 22,429 6.0%
2026-07-14 4,082 0 23,512 17.4%
2026-07-13 5,366 0 36,806 14.6%
2026-07-10 14,060 0 77,164 18.2%
2026-07-09 7,720 0 24,491 31.5%
2026-07-08 24,711 0 36,850 67.1%
2026-07-07 7,712 0 25,876 29.8%
2026-07-06 63,959 0 105,461 60.6%
2026-07-02 71,997 0 122,440 58.8%
2026-07-01 43,569 0 54,605 79.8%
2026-06-30 21,623 0 27,200 79.5%
2026-06-29 3,680 0 7,347 50.1%
2026-06-26 1,736 0 3,838 45.2%
2026-06-25 7,530 0 13,099 57.5%
2026-06-24 200 0 4,885 4.1%
2026-06-23 8,782 0 11,852 74.1%
2026-06-22 14,439 0 25,816 55.9%
2026-06-18 5,026 0 6,947 72.3%
2026-06-17 4,991 0 5,869 85.0%
2026-06-16 1,714 0 5,458 31.4%
2026-06-15 11,020 0 14,417 76.4%
2026-06-12 1,195 0 5,760 20.7%
2026-06-11 3,650 0 4,412 82.7%
2026-06-10 16,646 0 32,971 50.5%
2026-06-09 1,550 0 7,792 19.9%
2026-06-08 2,582 0 11,561 22.3%
2026-06-05 9,248 0 28,003 33.0%
2026-06-04 1,849 0 9,106 20.3%
2026-06-03 6,330 0 7,266 87.1%
2026-06-02 2,634 0 4,904 53.7%
2026-06-01 25,039 0 43,023 58.2%
2026-05-29 300 0 4,524 6.6%
2026-05-28 1,199 0 13,348 9.0%
2026-05-27 3,197 0 5,709 56.0%
2026-05-26 14,609 0 26,518 55.1%
2026-05-22 710 0 1,817 39.1%
2026-05-21 10,001 0 27,334 36.6%
2026-05-20 410 0 1,431 28.7%
2026-05-19 2,850 0 6,355 44.8%
2026-05-18 9,000 0 15,755 57.1%
2026-05-15 3,741 0 7,807 47.9%
2026-05-14 1,673 0 6,316 26.5%
2026-05-13 100 0 1,228 8.1%
Showing 1–50 of 60 days
Key facts CIK 1137883 CUSIP 10501E300 Visit website Investor relations